Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo Nodularis

NCT07276425 · clinicaltrials.gov ↗

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Prurigo Nodularis (PN)

Interventions

DRUG: Dupilumab

Sponsor

UMC Utrecht

Collaborators

[object Object]